This is how the Install App dialog will look like once your App goes live.
European NewsEU approval recommended for three drugs from AstraZenecaAstraZeneca has announced that three of its drugs have been recommended for EU approval. The three drugs are: Imfinzi, Enhertu and Lynparza, all of which can be used to treat different cancers.Imfinzi can be used in combination with chemotherapy as an immunotherapy treatment for advanced biliary tract cancer; Enhertu can be used for patients with previously treated HER2-positive advanced gastric cancer; and Lynparza can be used in combination with abiraterone to treat metastatic castration-resistant prostate cancer.In the PROpel phase 3 trial, Lynparza, in combination with abiraterone and prednisone or prednisolone, reduced the risk of disease progression or death by 34% in comparison with abiraterone alone. Progression-free survival was 24.8 months for Lynparza with abiraterone, compared to 16.6 months for just abiraterone.Susan Galbraith, AstraZeneca’s executive vice president of oncology R&D, said, “If approved, Lynparza in combination with abiraterone and prednisone or prednisolone will represent the first combination of a PARP inhibitor and new hormonal agent available to patients in the EU.”Results from the TOPAZ-1 phase 3 trial showed that Imfinzi alongside chemotherapy reduced the risk of death by 20% compared to chemotherapy alone. The median overall survival is reported as 12.9 months with Imfinzi, compared to 11.3 with chemotherapy alone.Susan Galbraith commented: “If approved, Imfinzi plus chemotherapy will provide patients with advanced biliary tract cancer the first opportunity for treatment with an immunotherapy-based combination.”Finally, results from the DESTINY-Gastric02 and DESTINY-Gastric01 phase 2 trials, showed Enhertu had a confirmed objective response rate of 41.8%. The average duration of response was 8.1 months, while average overall survival was 12.2 months. The drug saw a 40% reduction in the risk of death compared to patients treated with chemotherapy alone.Susan Galbraith added: “Gastric cancer is usually diagnosed in the advanced stage in many European countries and patients face high mortality rates. If approved, Enhertu would be the first HER2-directed medicine for patients with advanced gastric cancer in the European Union in more than a decade.”